COR588

Cortexyme Inc. · Phase 1 active Small molecule

COR588 is a small molecule in Phase 1 development by Cortexyme Inc. for undisclosed indications. The drug has completed a single and multiple ascending dose study with no reported safety concerns.

At a glance

Generic name	COR588
Sponsor	Cortexyme Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

COR588 CI brief — competitive landscape report
COR588 updates RSS · CI watch RSS
Cortexyme Inc. portfolio CI